Monitoring Cytokeratin Fragment 19 (CYFRA 21-1) Serum Levels for Early Prediction of Recurrence of Adenocarcinoma and Squamous Cell Carcinoma in the Lung after Surgical Resection

Yeh, Jun-Jun; Liu, Feng-Yuan; Hsu, Wu‐Huei; Wang, J.-J.; Ho, Shung‐Tai; Kao, Albert

doi:10.1007/s004080000101

Cited by 17 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, independent prognostic value of lactate dehydrogenase, albumin, calcium, NSE, CEA, and DNA have been observed in various studies 7,14,18–20 . For monitoring systemic therapy and the early detection of recurrent disease in non‐small cell lung cancer patients, CYFRA 21–1 and circulating DNA were frequently reported to be useful 6,12–15,21–23 . However, little is known about the relevance of biochemical markers for the early prediction of therapy response prior to imaging techniques.…”

Section: Discussionmentioning

confidence: 99%

Early and Specific Prediction of the Therapeutic Efficacy in Non–Small Cell Lung Cancer Patients by Nucleosomal DNA and Cytokeratin‐19 Fragments

Holdenrieder

Stieber

Pawel

et al. 2006

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Facing an era of promising new antitumor therapies, predictors of therapy response are needed for the individual management of treatment. In sera collected prospectively from 311 patients with advanced non-small cell lung cancer receiving first-line chemotherapy, changes in nucleosomal DNA fragments, cytokeratin-19 fragments (CYFRA 21-1), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and progastrin-releasing peptide (ProGRP) were investigated and correlated with therapy response. In univariate analysis, high levels, slower and incomplete decline in nucleosomal DNA, CYFRA 21-1, and CEA predicted poor outcome. DNA concentrations at day 8 of the first therapeutic cycle and CYFRA 21-1 before start of the second cycle were identified as best predictive variables. In multivariate analysis, they predicted progression with a specificity of 100% in 29% of the cases earlier than imaging techniques. Thus, nucleosomal DNA and CYFRA 21-1 specifically identify a subgroup of patients with insufficient therapy response at the early treatment phase and showed to be valuable for disease management.

show abstract

Section: Discussionmentioning

confidence: 99%

Early and Specific Prediction of the Therapeutic Efficacy in Non–Small Cell Lung Cancer Patients by Nucleosomal DNA and Cytokeratin‐19 Fragments

Holdenrieder

Stieber

Pawel

et al. 2006

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…The good correlation of tumor markers with tumor recurrences, which was associated in some cases with a considerable lead time, was confirmed by further studies for CYFRA 21-1 in patients with adeno-and squamous cell cancer [7,36]. TPS was found to be superior to SCC concerning the detection of recurrent disease in the squamous cancer cell subtype [12], and superior to CEA in the adenocancer cell subtype [32].…”

Section: Detection Of Recurrent Diseasementioning

confidence: 50%

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

Barak

Holdenrieder

Nisman

et al. 2010

CBM

View full text Add to dashboard Cite

As the release and amount of circulating biomarkers show considerable variations between individuals, single value determinations are often difficult to be interpreted on their diagnostic or prognostic significance on the individual level. However, changes of the biomarker levels in a specific person during the disease course are quite informative for the estimation of the efficacy of therapy or the early detection of recurrent disease because they consider only intraindividual variations. If methods for marker determination are maintained, preanalytical and analytical standard prerequistits are respected, thresholds for each marker have to be defined which exceeds the normal, intraindividual biological variation. Then continuous biomarker increases may be indicative for disease activity in terms of inefficient therapy response or tumor recurrence while decreasing values often are associated with activity reduction of cancer disease. Here, we review the current knowledge on biomarker kinetics in patients with non-small cell lung cancer (NSCLC) and discuss the conditions and pitfalls of their relevance for the estimation efficacy of therapy and the early detection of recurrent disease. Further, we suggest a scenario to reveal the power of the defined biomarker use in future and to include those markers into the individual management of NSCLC patients.

show abstract

“…Serum CYFRA 21-1 level was not influenced by sex and smoking habits [38, 39], which was found to be an independent prognostic factor of survival and tumour relapse [40]. The meta-analysis about prognostic significance of CYFRA 21-1 has been studied in several articles, which have indicated that high level expression of CYFRA 21-1 implies a poor prognosis [32, 34, 41–48]. In this study, we found that the 2-year overall survival in the high level group was significantly lower than that in the low level group group, which is consistant with studies previous.…”

Section: Discussionmentioning

confidence: 99%

Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis

Zhang

Yang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

AIMTo evaluate the value of Cytokeratin 19 fragment for its survival prognostic indicator and predictive correlation with clinicopathological features in Non-small Cell Lung Cancer.METHODSEligible studies or databases for articles were retrieved via search systematically. Pooled effect was calculated to evaluate the association between Cytokeratin 19 fragment level and long-term overall survival, as well as the tumor clinicopathological features in Non-small Cell Lung Cancer patients. A fixed-effects or random-effects model was used to calculate the Pooled risk ratios (RRs) and corresponding 95 % confidence intervals (CIs).RESULTSSix studies were up to the selection criteria. This meta-analysis indicated that Cytokeratin 19 fragment high level expression correlated with lower 2-year overall survival (RR =0.47; 95%CI: 0.28-0.79), higher Tumor Node Metastasis stage (II+III+IV) (RR =1.43; 95%CI: 1.15-1.76) in Non-small Cell Lung Cancer. The pooled RR estimates indicated that there is no statistical significance of Cytokeratin 19 fragment level expression in the advanced Non-small Cell Lung Cancer (IIIB+IV) (RR =1.43, 95% CI: 0.85-2.43).CONCLUSIONCytokeratin 19 fragment is a negative prognosis indicator and its high level expression indicates higher Tumor Node Metastasis pathological stage (II+III+IV) in Non-small Cell Lung Cancer. In advanced Non-small Cell Lung Cancer, the level of serum Cytokeratin 19 fragment appears to provide more prognostic information than it does for clinical Tumor Node Metastasis stage information. Further studies are required to confirm our results.

show abstract

Monitoring Cytokeratin Fragment 19 (CYFRA 21-1) Serum Levels for Early Prediction of Recurrence of Adenocarcinoma and Squamous Cell Carcinoma in the Lung after Surgical Resection

Cited by 17 publications

References 19 publications

Early and Specific Prediction of the Therapeutic Efficacy in Non–Small Cell Lung Cancer Patients by Nucleosomal DNA and Cytokeratin‐19 Fragments

Early and Specific Prediction of the Therapeutic Efficacy in Non–Small Cell Lung Cancer Patients by Nucleosomal DNA and Cytokeratin‐19 Fragments

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis

Contact Info

Product

Resources

About